These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8185351)

  • 1. [Chemotherapy with oral etoposide, UFT and carboplatin in non-small cell lung cancer].
    Kinoshita T; Akaogi E; Mitsui K; Onizuka M; Ishikawa S; Morita R; Ishibashi O; Suga M; Inagaki M; Okazaki H
    Gan To Kagaku Ryoho; 1994 May; 21(6):891-4. PubMed ID: 8185351
    [No Abstract]   [Full Text] [Related]  

  • 2. [Combination chemotherapy with continuous infusion of low-dose cisplatin and UFT for advanced non-small cell lung cancer].
    Seike M; Andoh M; Hasegawa K; Sakonji M; Tsuboi E
    Gan To Kagaku Ryoho; 1998 Aug; 25(10):1539-42. PubMed ID: 9725046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An successful case of combined daily oral administration of UFT and low-dose etoposide for multiple metastases of lung cancer].
    Imaizumi M; Takeuchi M; Seki Y; Yoshioka H; Yamada K
    Gan To Kagaku Ryoho; 2000 Jul; 27(7):1035-8. PubMed ID: 10925690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot trial of a combination comprising of consecutive oral administration of UFT, and two-divided administration of CDDP in non-small cell lung cancer.
    Gemma A; Kudoh S; Yoshimura A; Ono Y; Takenaka K; Hayashihara K; Hino M; Shibuya M; Niitani H
    Anticancer Res; 1995; 15(6B):2691-5. PubMed ID: 8669849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study.
    Gridelli C; Rossi A; Scognamiglio F; Guida C; Fiore F; Gatani T; Scoppa G; Pergola M
    Anticancer Res; 1997; 17(6D):4755-8. PubMed ID: 9494602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [UFT plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer--its application to outpatient practice].
    Yano T; Koga T; Nomiyama H; Hidaka H
    Gan To Kagaku Ryoho; 2003 Jul; 30(7):959-62. PubMed ID: 12894710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemotherapy with cisplatin and daily administration of UFT for unresectable non-small cell lung cancer].
    Takanashi N; Hara N; Ichinose Y; Asoh H; Yano T; Yokoyama H; Miura T; Matsuoka Y; Tayama K; Ohta M
    Gan To Kagaku Ryoho; 1993 May; 20(7):921-7. PubMed ID: 8387761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant UFT therapy does not increase survival in people with resected stage 1 non-small cell lung cancer.
    Stewart L; Burdett S
    Cancer Treat Rev; 2005 Oct; 31(6):487-90. PubMed ID: 16185813
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of unresectable non-small cell lung cancer (NSCLC) with carboplatin and chronic daily administration of oral etoposide].
    Hirabayashi M; Tanaka Y; Yoshida H; Nakagawa M; Kuno K
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):53-8. PubMed ID: 8291916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
    Strauss GM; Lynch TJ; Elias AD; Jacobs C; Herbst R; Leong T; Lynch C; Kwiatkowski DJ; Carey RW; Grossbard ML; Skarin AT
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-73-S12-80. PubMed ID: 9331127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
    Miyoshi T; Kondo K; Toba H; Yoshida M; Fujino H; Kenzaki K; Sakiyama S; Takehisa M; Tangoku A
    Anticancer Res; 2007; 27(4C):2641-8. PubMed ID: 17695427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer.
    Takayama K; Kawasaki M; Ninomiya K; Motohiro A; Fujita M; Watanabe K; Kajiki A; Iwami F; Miyazaki N; Izumi M; Hara N; Nakanishi Y;
    Respirology; 2008 Jan; 13(1):103-7. PubMed ID: 18197918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experimental evaluation of combination chemotherapy with UFT and cisplatin for lung cancer].
    Uchida J; Satake H; Saito H; Nakano K; Takeda S; Unemi N
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):1001-8. PubMed ID: 8210249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase II study of combination chemotherapy with cisplatin, carboplatin and etoposide (CPVP) in unresectable non-small cell lung cancer: analysis of survival time and prognostic factors].
    Sakurai M; Ichiki M; Hayashi I
    Gan To Kagaku Ryoho; 1997 Feb; 24(3):303-8. PubMed ID: 9051132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A phase II study of UFT in non-small cell lung cancer].
    Shimizu E; Kimura K; Sone S; Inoue I; Nakamura Y; Noda Y; Hojo F; Yagi M; Nakanishi S; Yamasaki K
    Gan To Kagaku Ryoho; 1986 Oct; 13(10):2970-3. PubMed ID: 3021068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dramatic response to uracil-tegafur (UFT) in an elderly patient with nonsmall cell lung cancer.
    Kanaji N; Bandoh S; Ishida T
    South Med J; 2007 Oct; 100(10):1056-7. PubMed ID: 17943058
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
    Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB
    Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer.
    Rosell R; Felip E; Massuti B; González-Larriba JL; Benito D; López-Cabrerizo MP; Salamanca O; Camps C; Puerto-Pica J
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-56-S12-60. PubMed ID: 9331123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase II study of a novel combination regimen composed of cisplatin, carboplatin and etoposide against unresectable non-small cell lung cancer].
    Sakurai M; Ichiki M; Ohashi Y; Hayashi I
    Gan To Kagaku Ryoho; 1993 Mar; 20(4):499-502. PubMed ID: 8383950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.